FY2025 Earnings Estimate for Amgen Issued By William Blair

Key Points

• William Blair has raised its FY2025 earnings per share forecast for Amgen to $20.90, reflecting confidence in the company's performance, up from a previous estimate of $20.86.
• Amgen reported a quarterly earnings per share of $6.02, significantly exceeding analysts' consensus estimates, while its revenue grew 9.4% year-over-year.
• The company recently declared a quarterly dividend of $2.38, yielding approximately 3.3%, with a payout ratio of 77.84%.

Amgen Inc. (NASDAQ:AMGN - Free Report) - Stock analysts at William Blair boosted their FY2025 earnings per share (EPS) estimates for Amgen in a research report issued to clients and investors on Friday, October 10th. William Blair analyst M. Phipps now forecasts that the medical research company will earn $20.90 per share for the year, up from their prior forecast of $20.86. William Blair currently has a "Outperform" rating on the stock. The consensus estimate for Amgen's current full-year earnings is $20.62 per share.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its earnings results on Tuesday, August 5th. The medical research company reported $6.02 EPS for the quarter, beating analysts' consensus estimates of $5.28 by $0.74. The company had revenue of $9.18 billion during the quarter, compared to the consensus estimate of $8.86 billion. Amgen had a return on equity of 174.71% and a net margin of 18.96%.The firm's revenue for the quarter was up 9.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $4.97 earnings per share. Amgen has set its FY 2025 guidance at 20.200-21.300 EPS.

AMGN has been the subject of a number of other research reports. UBS Group decreased their price objective on Amgen from $326.00 to $317.00 and set a "neutral" rating for the company in a report on Wednesday, August 6th. Bank of America increased their price objective on Amgen from $261.00 to $272.00 and gave the stock an "underperform" rating in a report on Friday, September 26th. Piper Sandler increased their price objective on Amgen from $328.00 to $342.00 and gave the stock an "overweight" rating in a report on Monday, August 25th. Raymond James Financial started coverage on Amgen in a report on Wednesday, September 3rd. They issued a "market perform" rating for the company. Finally, Wall Street Zen downgraded Amgen from a "buy" rating to a "hold" rating in a report on Saturday. Eight equities research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $309.42.

Amgen Price Performance

AMGN opened at $290.13 on Monday. The stock has a fifty day simple moving average of $286.77 and a two-hundred day simple moving average of $287.43. The company has a current ratio of 1.31, a quick ratio of 0.98 and a debt-to-equity ratio of 7.24. The company has a market cap of $156.19 billion, a price-to-earnings ratio of 23.72, a price-to-earnings-growth ratio of 2.52 and a beta of 0.49. Amgen has a 12-month low of $253.30 and a 12-month high of $335.88.

Amgen Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, September 12th. Stockholders of record on Friday, August 22nd were paid a $2.38 dividend. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.3%. The ex-dividend date of this dividend was Friday, August 22nd. Amgen's dividend payout ratio is currently 77.84%.

Insider Activity at Amgen

In other news, SVP Nancy A. Grygiel sold 1,267 shares of the stock in a transaction on Wednesday, August 20th. The stock was sold at an average price of $296.99, for a total value of $376,286.33. Following the sale, the senior vice president directly owned 7,209 shares of the company's stock, valued at approximately $2,141,000.91. This represents a 14.95% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 0.69% of the company's stock.

Institutional Investors Weigh In On Amgen

Several institutional investors have recently modified their holdings of AMGN. Wealth Preservation Advisors LLC purchased a new stake in shares of Amgen during the first quarter valued at $25,000. Legacy Investment Solutions LLC purchased a new stake in shares of Amgen during the second quarter valued at $27,000. First Pacific Financial boosted its position in shares of Amgen by 304.5% during the first quarter. First Pacific Financial now owns 89 shares of the medical research company's stock valued at $28,000 after buying an additional 67 shares during the last quarter. CBIZ Investment Advisory Services LLC boosted its position in shares of Amgen by 1,214.3% during the first quarter. CBIZ Investment Advisory Services LLC now owns 92 shares of the medical research company's stock valued at $29,000 after buying an additional 85 shares during the last quarter. Finally, Evelyn Partners Investment Management LLP purchased a new stake in shares of Amgen during the second quarter valued at $32,000. 76.50% of the stock is owned by hedge funds and other institutional investors.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.